title: Changes in Wuchereria bancrofti infection in a highly endemic community following 10 rounds of mass administration of diethylcarbamazine.
abstract: Mass drug administration (MDA) is the principal strategy of the programme to eliminate lymphatic filariasis (LF). Evaluation of MDA in highly endemic 'sentinel' communities is necessary to understand its impact on LF infection. This study examined the changes in Wuchereria bancrofti infection following 10 rounds of annual mass administration of diethylcarbamazine (DEC) in a highly endemic community. The mean number of DEC treatments received per adult in the community was 7.4+/-2.0. Following 10 rounds of DEC administration, the number of microfilaria (mf) carriers fell from 565 to 55. None of the pre-MDA amicrofilaraemic individuals showed circulating filarial antigen (CFA). However, 54.5% of the pre-MDA microfilaraemic individuals were positive for CFA. All the pre-MDA high intensity mf carriers continued to be positive for CFA, and some of them also showed blood mf. These patients are the most difficult to be cured by MDA and were distributed in 8.2% of the households. All the children born during the last 7 years of the MDA programme were negative for CFA. The study suggests that six to seven DEC treatments per individual suppresses microfilaraemia, except in some people with heavy infection, and repeated MDA has very good potential to prevent infection in children.
authors.affiliation: Vector Control Research Centre (Indian Council of Medical Research), Medical Complex, Indira Nagar, Pondicherry 605006, India. ramaiahk@yahoo.com
authors.forename: K D
authors.initials: KD
authors.lastname: Ramaiah
authors.forename: P
authors.initials: P
authors.lastname: Vanamail
authors.forename: P K
authors.initials: PK
authors.lastname: Das
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000947:Antigens, Helminth / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D004049:Diethylcarbamazine / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004605:Elephantiasis, Filarial / Q000453:epidemiology / Q000517:prevention & control*; D019353:Endemic Diseases / Q000517:prevention & control; D005260:Female; D005369:Filaricides / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D018512:Parasitemia / Q000453:epidemiology / Q000517:prevention & control; D014958:Wuchereria bancrofti / Q000276:immunology / Q000302:isolation & purification*
chemical_list: D000947:Antigens, Helminth; D005369:Filaricides; D004049:Diethylcarbamazine